Combotope Therapeutics focuses on developing innovative cancer therapies through its proprietary antibody discovery platform, which targets aberrant O-glycosylation—a modification prevalent in 50-80% of cancers but absent in healthy cells. This unique approach allows for the precise identification of tumor-specific antibodies that bind to glycan-protein structures unique to cancer cells, thereby enabling the creation of monoclonal antibodies (mAbs) that selectively target tumors while sparing healthy tissue. The company boasts a diverse pipeline of tumor-selective mAbs, including Combotope-D3Y, which targets Mucin-1 with high affinity and minimal cross-reactivity, and Combotope-Tn/STn, a versatile antibody that can stain various tumor tissues.

In addition to its antibody development, Combotope offers a Companion Diagnostic Test (CCDx) to verify Tn/STn glycosylation on selected tumor targets, enhancing the precision of its therapies. The company maintains a comprehensive target database with over 900 O-glycosylated membrane proteins, allowing for extensive collaboration with clinical-stage partners to explore both established and novel therapeutic targets. This strategic focus on aberrant glycosylation positions Combotope as a leader in the field of cancer immunotherapy, aiming to provide safer and more effective treatment options for patients.

Denmark

Combotope Therapeutics has developed a proprietary mAb discovery platform designed to target cancer cells without impacting healthy cells. Our platform, known as integrated Design Antibody Libraries (iDEAL), combines glycan and peptide-focused scFv technology, providing antibodies that specifically target the tumor form of a particular protein on cancer cells while leaving healthy cells expressing the same, but correctly glycosylated protein, untouched. Our scFv sequences are of high affinity, making them suitable for easy integration into numerous therapeutic modalities for effective cancer treatment.

Combotope Therapeutics

Company Details